Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | 03/31/2010 | 12/31/2009 | 09/30/2009 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.32M | 2.14M | 2.38M | 2.34M | 2.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.15M | 3.14M | 4.62M | 5.32M | 7.63M |
| Operating Income | -2.15M | -3.14M | -4.62M | -5.32M | -7.63M |
| Income Before Tax | -2.51M | -3.64M | -6.39M | -5.79M | -8.15M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.51M | -3.64M | -6.39M | -5.79M | -8.15M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.51M | -3.64M | -6.39M | -5.79M | -8.15M |
| EBIT | -2.15M | -3.14M | -4.62M | -5.32M | -7.63M |
| EBITDA | -1.94M | -2.91M | -4.37M | -5.06M | -7.45M |
| EPS Basic | -0.08 | -0.11 | -0.22 | -0.21 | -0.30 |
| Normalized Basic EPS | -0.05 | -0.07 | -0.11 | -0.13 | -0.19 |
| EPS Diluted | -0.08 | -0.11 | -0.22 | -0.21 | -0.30 |
| Normalized Diluted EPS | -0.05 | -0.07 | -0.11 | -0.13 | -0.19 |
| Average Basic Shares Outstanding | 33.46M | 33.46M | 29.35M | 27.59M | 27.44M |
| Average Diluted Shares Outstanding | 33.46M | 33.46M | 29.35M | 27.59M | 27.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |